Morgan Stanley Maintains Overweight on Denali Therapeutics, Lowers Price Target to $91
Morgan Stanley maintains Denali Therapeutics (NASDAQ:DNLI) with a Overweight and lowers the price target from $99 to $91.
Jim Cramer Says This Stock Is ‘Really Cheap’
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Academy Sports and Outdoors (NYSE: ASO) is ”really cheap” and recommended buying the stock.
Denali Therapeutics Q3 EPS $(0.69) Down From $(0.54) YoY, Sales $5.28M Down From $9.39M YoY
Denali Therapeutics (NASDAQ:DNLI) reported quarterly losses of $(0.69) per share. This is a 27.78 percent decrease over losses of $(0.54) per share from the same period last year. The company reported $5.28 million in
The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 6)
Denali Highlights Encouraging Early Data, Update For Amyotrophic Lateral Sclerosis Program
Denali Therapeutics Inc (NASDAQ:DNLI) announced data from the Phase 1 trial evaluating DNL343, eIF2B activator, in 95 healthy volunteers. DNL343 was…
The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer’s Sleep Disorder Drug Filing Accepted For Review, Voyager’s Licensing Options Deal
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 5)
The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs And More
Biotech stocks came under pressure in the week ending Oct. 1, dragged by broader market weakness and the selling of vaccine stocks.
Oppenheimer Initiates Coverage On Denali Therapeutics with Outperform Rating, Announces Price Target of $85
Oppenheimer analyst Jay Olson initiates coverage on Denali Therapeutics (NASDAQ:DNLI) with a Outperform rating and announces Price Target of $85.